Patents Assigned to ATTOQUANT DIAGNOSTICS GMBH
-
Patent number: 11079398Abstract: The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.Type: GrantFiled: May 5, 2017Date of Patent: August 3, 2021Assignee: ATTOQUANT DIAGNOSTICS GMBHInventors: Marko Poglitsch, Cornelia Schwager, Hans Loibner, Manfred Schuster
-
Patent number: 10295552Abstract: Methods and kits for the diagnosis of primary hyperaldosteronism (PHA). In particular, the present invention relates to the use of a new diagnostic parameter that is composed of the ratio between the Ang II level, in particular the steady state equilibrium Ang II level, and the aldosterone level in a biological sample, such as e.g. plasma. The ratio of the two measured parameters is used to diagnose PHA in patients and has clear advantages over currently used diagnostic methods.Type: GrantFiled: October 20, 2017Date of Patent: May 21, 2019Assignee: ATTOQUANT DIAGNOSTICS GMBHInventors: Marko Poglitsch, Cornelia Schwager, Dunja Van Oyen, Martin Leitner
-
Publication number: 20180164330Abstract: Methods and kits for the diagnosis of primary hyperaldosteronism (PHA). In particular, the present invention relates to the use of a new diagnostic parameter that is composed of the ratio between the Ang II level, in particular the steady state equilibrium Ang II level, and the aldosterone level in a biological sample, such as e.g. plasma. The ratio of the two measured parameters is used to diagnose PHA in patients and has clear advantages over currently used diagnostic methods.Type: ApplicationFiled: October 20, 2017Publication date: June 14, 2018Applicant: ATTOQUANT DIAGNOSTICS GMBHInventors: Marko POGLITSCH, Cornelia SCHWAGER, Dunja VAN OYEN, Martin LEITNER
-
Patent number: 9839668Abstract: The present invention relates to a pharmaceutical composition comprising a. at least one aspartyl aminopeptidase inhibitor and at least one angiotensin-converting-enzyme (ACE) inhibitor, or b. at least one aspartyl aminopeptidase inhibitor and at least one chymase inhibitor. In an embodiment, the pharmaceutical composition comprises at least one aspartyl aminopeptidase inhibitor and at least one angiotensin-converting-enzyme (ACE) inhibitor and at least one chymase inhibitor. Furthermore, the invention relates to a pharmaceutical composition possessing inhibitory activity against a. aspartyl aminopeptidase and angiotensin-converting-enzyme (ACE), or b. against aspartyl aminopeptidase and chymase. In a third aspect, the invention relates to a kit of parts comprising a. a pharmaceutical composition comprising an aspartyl aminopeptidase inhibitor and a pharmaceutical composition comprising an angiotensin-converting-enzyme (ACE) inhibitor, or b.Type: GrantFiled: December 11, 2014Date of Patent: December 12, 2017Assignee: ATTOQUANT DIAGNOSTICS GMBHInventors: Marko Poglitsch, Cornelia Schwager, Hans Loibner
-
Patent number: 9829496Abstract: Methods and kits for the diagnosis of primary hyperaldosteronism (PHA). In particular, the use of a new diagnostic parameter that is composed of the ratio between the Ang II level, in particular the steady state equilibrium Ang II level, and the aldosterone level in a biological sample, such as e.g. plasma. The ratio of the two measured parameters is used to diagnose PHA in patients and has clear advantages over currently used diagnostic methods.Type: GrantFiled: October 17, 2014Date of Patent: November 28, 2017Assignee: ATTOQUANT DIAGNOSTICS GMBHInventors: Marko Poglitsch, Cornelia Schwager, Dunja Van Oyen, Martin Leitner
-
Publication number: 20170285048Abstract: The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.Type: ApplicationFiled: May 5, 2017Publication date: October 5, 2017Applicant: ATTOQUANT DIAGNOSTICS GMBHInventors: Marko Poglitsch, Cornelia Schwager, Hans Loibner, Manfred Schuster
-
Patent number: 9684004Abstract: The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade (for example, the renin-angiotensin system (RAS) and the bradykinin system) in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.Type: GrantFiled: June 6, 2012Date of Patent: June 20, 2017Assignee: ATTOQUANT DIAGNOSTICS GMBHInventors: Marko Poglitsch, Cornelia Schwager, Hans Loibner, Manfred Schuster
-
Publication number: 20160310562Abstract: The present invention relates to a pharmaceutical composition comprising a. at least one aspartyl aminopeptidase inhibitor and at least one angiotensin-converting-enzyme (ACE) inhibitor, or b. at least one aspartyl aminopeptidase inhibitor and at least one chymase inhibitor. In an embodiment, the pharmaceutical composition comprises at least one aspartyl aminopeptidase inhibitor and at least one angiotensin-converting-enzyme (ACE) inhibitor and at least one chymase inhibitor. Furthermore, the invention relates to a pharmaceutical composition possessing inhibitory activity against a. aspartyl aminopeptidase and angiotensin-converting-enzyme (ACE), or b. against aspartyl aminopeptidase and chymase. In a third aspect, the invention relates to a kit of parts comprising a. a pharmaceutical composition comprising an aspartyl aminopeptidase inhibitor and a pharmaceutical composition comprising an angiotensin-converting-enzyme (ACE) inhibitor, or b.Type: ApplicationFiled: December 11, 2014Publication date: October 27, 2016Applicant: ATTOQUANT DIAGNOSTICS GMBHInventors: Marko POGLITSCH, Cornelia SCHWAGER, Hans LOIBNER
-
Publication number: 20160266151Abstract: The present invention relates to methods and kits for the diagnosis of primary hyperaldosteronism (PHA). In particular, the present invention relates to the use of a new diagnostic parameter that is composed of the ratio between the Ang II level, in particular the steady state equilibrium Ang II level, and the aldosterone level in a biological sample, such as e.g. plasma. The ratio of the two measured parameters is used to diagnose PHA in patients and has clear advantages over currently used diagnostic methods.Type: ApplicationFiled: October 17, 2014Publication date: September 15, 2016Applicant: ATTOQUANT DIAGNOSTICS GMBHInventors: Marko Poglitsch, Cornelia Schwager, Dunja Van Oyen, Martin Leitner
-
Publication number: 20150050676Abstract: The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade (for example, the renin-angiotensin system (RAS) and the bradykinin system) in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.Type: ApplicationFiled: June 6, 2012Publication date: February 19, 2015Applicant: ATTOQUANT DIAGNOSTICS GMBHInventors: Marko Poglitsch, Cornelia Schwager, Hans Loibner, Manfred Schuster